Table 1 –
Univariable analysis comparing clinical and tumor characteristics of patients with benign disease versus those with malignant disease.
| Characteristic | Benign cohort, n = 25 (%) | Malignant cohort, n = 10 (%) | P-value |
|---|---|---|---|
| Gender | 0.283 | ||
| Male | 10 (40) | 6 (60) | |
| Female | 15 (60) | 4 (40) | |
| Race | 0.717 | ||
| Caucasian | 20 (80) | 9 (90) | |
| African American | 4 (16) | 1 (10) | |
| Asian | 1 (4) | 0 (0) | |
| Unknown | 0 (0) | 0 (0) | |
| Age at time of operation (y) | 38 ± 20 | 38 ± 14 | 0.930 |
| Primary tumor site | 0.333 | ||
| Adrenal | 17 (68) | 7 (70) | |
| Periaortic | 3 (12) | 1 (10) | |
| Bladder | 0 (0) | 1 (10) | |
| Neck/paratracheal | 1 (4) | 1 (10) | |
| Retroperitoneal | 4 (16) | 0 (0) | |
| Genetics | 0.262 | ||
| No germline genetic mutation | 13 (52) | 2 (20) | |
| SDHB | 6 (24) | 4 (40) | |
| VHL | 3 (12) | 2 (20) | |
| MEN2A | 1 (4) | 0 (0) | |
| HIF2a | 0 (0) | 1 (10) | |
| MAX | 0 (0) | 1 (10) | |
| KIF1B | 1 (4) | 0 (0) | |
| NF1 | 1 (4) | 0 (0) | |
| Postoperative biochemical response | 0.207 | ||
| Partial biochemical response | 2 (8) | 2 (20) | |
| Complete biochemical response | 20 (80) | 5 (50) | |
| Unknown | 3 (12) | 3 (30) | |
| Body mass index at time of operation (kg/m2) | 27.9 ± 8.4 | 29.1 ± 6.3 | 0.692 |
| Serum miR-210 level (normalized) | 3.0987 ± 1.2278 | 2.3299 ± 0.5078 | 0.013 |
| Tumor size (cm) | 4.1 ± 2.3 | 6.7 ± 5.0 | 0.03 |
Categorical values expressed as n (%) rounded to the nearest percentage. Continuous variables expressed as mean ± standard deviation. The miR-210 expression level is normalized.
SDHB = succinate dehydrogenase complex subunit B mutation; VHL = von Hippel-Lindau disease; MEN2A = multiple endocrine neoplasia type 2A; HIF2a = hypoxia-inducible factor a mutation; MAX = myc-associated factor X mutation; KIF1B = kinesin family member 1B mutation; NF1 = neurofibromatosis 1.